The new good pharmacovigilance practice chapter IV on specific considerations for the pediatric population offers a holistic view of pediatric pharmacovigilance and provides guidance on how to address the specific needs and challenges of safety monitoring of medicines used in children.
This article discusses why it is important to apply risk analysis, QbD, and DoE in the development of analytical methods.
Rather than isolating the user in a virtual world, mixed reality allows contextualized data to be shared in real time, improving assays, standard operating procedures, workflows, and overall tech transfer.
The agency sent a warning letter to the company for marketing an unapproved stem cell product and CGMP violations.
The agency is developing a new way to assess, record, and report data from surveillance and preapproval inspections of sterile drugs.
Pharma companies are concerned they may have to postpone plans for the commercialization of new combination products because of delays in obtaining marketing authorizations because of a lack of clarity about approval rules.
Investigatory work arranged by Swissmedic has revealed that sartan-containing medicines on the Swiss market are safe in respect of NDMA.
The new program will provide cell and gene therapy companies a more efficient way to ensure quality compliance across collection center networks and to minimize quality system audit burden on these centers.
Leaders of the two parties are open to challenging the status quo on drug costs and spending.
The decision follows an FDA request for additional information to complement the company’s submission for biosimilar rituximab.
An ERP solution provides for the management of multiple business activities and traceability requirements resulting from regulations, customer demands, sourcing, and international business needs.
Building up relevant expertise in-house will make writing spec sheets for software easier, according to Siegfried Schmitt, principal consultant at PAREXEL.
This paper describes how the concept of acceptance value can be redefined to remove bias and more closely reflect quality targets.
Survey results and record attendance show positive signs for various bio/pharma regions.
Experts share best practices, and war stories, for a crucial but often underappreciated part of drug development.
New FDA guidance offers a time buffer but increases supply-chain-management complexity, as active DSCSA enforcement begins.
A statement from FDA Commissioner Scott Gottlieb and Deputy Commissioner Anna Abram detailed FDA’s new plan to advance plant and animal biotechnology innovation.
Mock inspections-if conducted properly-can prepare a pharma company for the day FDA knocks on the door.
The companies announced the European launch of Imraldi (adalimumab), a biosimilar referencing AbbVie’s blockbuster Humira (adalimumab).
Mylan announced the launch of its biosimilar to AbbVie’s Humira across major European markets.
A new proposal aims to reduce reimbursement for medicines administered to seniors under the Part B benefit to an amount pegged to the average price paid in foreign industrial nations.
The agency has approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza.
Takhzyro (lanadelumab) is the first monoclonal antibody therapy approved for the prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.
Promise Pharmacy recalls one lot of Prednisolone and Gatifloxacin Ophthalmic Solution 1%/0.5% sterile, 3mL vials due to particulates in the solution.
The recommended drugs include one biosimilar, two orphan medicines, and three extensions of therapeutic indication.